Full-Time

Senior Specialty Representative

Bone Health

Posted on 5/10/2025

Amgen

Amgen

10,001+ employees

Biotechnology company developing therapeutic medicines

Compensation Overview

$125.1k - $148.1k/yr

+ Bonus + Sales-based Incentive Plan

Senior

Palmdale, CA, USA + 2 more

More locations: Bakersfield, CA, USA | Santa Clarita, CA, USA

Territory includes: Bakersfield, Lancaster, Palmdale, Valencia, Santa Clarita. Relocation is not offered for this role.

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Requirements
  • Bachelor's Degree and 3 years of sales experience
  • OR
  • Associate degree and 6 years of sales experience
  • OR
  • High school diploma/GED and 8 years of sales experience
Responsibilities
  • Provide current and comprehensive knowledge of Amgen's products and effectively communicate the clinical benefits to medical professionals to drive appropriate utilization of the products
  • Perform as a sales leader to achieve territory sales by delivering branded sales messages, conducting planned programs, scheduling and following-up with medical educational programs, and achieving or exceeding sales targets through both in-person and virtual engagement
  • Develop relationships to service and manage accounts which may include: customizing discussions and customer interactions based on understanding of customer needs, ensuring product access, resolving/triage reimbursement issues, and maintaining product contracts
  • Provide feedback on marketing strategy, analyze business effectiveness of sales activities and territory analysis, and develop territory plans with the District Manager
  • Partner with other colleagues to share best practices and seek to learn and grow as a Senior Specialty Representative
  • Demonstrate passion for our products and sustain that passion through the entire sales cycle while always building our brand and never losing sight of how we serve patients
  • Uphold Amgen Values: Be Science-Based; Compete Intensely and Win; Create Value for Patients, Staff, and Stockholders; Be Ethical; Trust and Respect Each Other; Ensure Quality; Work in Teams; Collaborate, Communicate, and Be Accountable
Desired Qualifications
  • Sales, marketing and/or clinical experience within pharmaceutical, biotech, diagnostics, healthcare insurance, pharmacy services, healthcare medical device or medical supply industries
  • Some experience and/or pre-graduate sales training and/or proven track record of successful leadership under pressure preferred for Specialty Representative
  • 3 years+ experience preferred for Senior Specialty Representative
  • Product or hospital sales experience in the areas of oncology, cardiology, inflammation, nephrology, dermatology, rheumatology, neurology, endocrinology, hepatology, gastroenterology, bone health, respiratory, hematology, or infectious diseases; and the diseases and treatments involved with these specialties
  • Advanced influencing and relationship-building skills with a focus on sales outcomes
  • Local Market knowledge
  • Bachelor's degree in Life Sciences or Business Administration
  • Adaptability with our Core Competencies: Sales Planning and Organizing; Leveraging Business, Industry, and Technical Knowledge; Communicating with Impact; Driving for Results; and Cultivating Internal and External Relationships.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and commercializes biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a significant portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.